Comparing Dexmedetomidine Infusion and Bolus Doses Before Intubation
Effect of Dexmedetomidine Infusion Dose Versus Rapid Bolus Dose on Hemodynamic Changes During Laryngoscopy and Tracheal Intubation in Adults. A Randomized Comparative Study.
PHASE2 · Kasr El Aini Hospital · NCT06327399
This study is testing whether giving a steady drip or a quick dose of Dexmedetomidine before intubation helps keep patients' heart rate and blood pressure stable during surgery.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | Kasr El Aini Hospital (other) |
| Locations | 1 site (Giza) |
| Trial ID | NCT06327399 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of two different dosing methods of Dexmedetomidine—infusion versus bolus—on hemodynamic stability during tracheal intubation in patients undergoing elective surgery. Patients will be randomly assigned to receive either a continuous infusion or a rapid bolus of Dexmedetomidine prior to anesthesia induction. The study will monitor heart rate, blood pressure, and oxygen saturation to assess the safety and efficacy of each method. The goal is to determine which dosing method results in fewer complications such as bradycardia and hypertension during intubation.
Who should consider this trial
Good fit: Ideal candidates are ASA I and II patients with Mallampati grades I and II undergoing elective surgeries.
Not a fit: Patients with morbid obesity, predicted difficult airways, or those with uncontrolled sepsis will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved safety and reduced complications during tracheal intubation for surgical patients.
How similar studies have performed: Previous studies have shown varying results with Dexmedetomidine dosing methods, making this approach both relevant and potentially novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ASA I and II patients. * Mallampati grade I and II. Exclusion Criteria: * Patient refusal. * Morbid obesity. * Predicted difficult airway/unanticipated difficult intubation or laryngoscopic attempt lasting greater than 15 seconds or two attempts or more. * Patients with uncontrolled sepsis. * Pregnancy or breast feeding. * Patients with renal impairment i.e. SCr ≥ 1.5 * Any patient on regular intake of beta blockers or calcium channel blockers. * CNS disorders.
Where this trial is running
Giza
- Cairo University Hospitals — Giza, Egypt (RECRUITING)
Study contacts
- Study coordinator: Ramy m alkonaiesy, MD
- Email: ramyalkonaiesy@gmail.com
- Phone: 01224883990
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Dexmedetomidine, Intubation Complication